Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer
Publication Date: August 10, 2017
Last Updated: March 14, 2022
Recommendations
Initial patient evaluation and counseling
Before treatment consideration, a full history and physical examination should be performed, including an examination under anesthesia, at the time of transurethral resection of bladder tumor (TURBT) for a suspected invasive cancer. (CP)
324527
Before muscle-invasive bladder cancer management, clinicians should perform a complete staging evaluation, including imaging of the chest and cross-sectional imaging of the abdomen and pelvis with intravenous contrast if not contraindicated. Laboratory evaluation should include a comprehensive metabolic panel (complete blood count, liver function tests, alkaline phosphatase, and renal function). (CP)
324527
An experienced genitourinary pathologist should review the pathology of a patient when variant histology is suspected or if muscle invasion is equivocal (eg, micropapillary, nested, plasmacytoid, neuroendocrine, sarcomatoid, extensive squamous or glandular differentiation). (CP)
324527
Before treatment, clinicians should counsel patients regarding complications and the implications of treatment on quality of life (eg, impact on continence, sexual function, fertility, bowel dysfunction, metabolic problems). (CP)
324527
For patients with newly diagnosed muscle-invasive bladder cancer, curative treatment options should be discussed before determining a plan of therapy that is based on both patient comorbidity and tumor characteristics. Patient evaluation should be completed using a multidisciplinary approach. (CP)
324527
Treatment
Neoadjuvant and adjuvant chemotherapy
Using a multidisciplinary approach, clinicians should offer cisplatin-based neoadjuvant chemotherapy to eligible patients undergoing radical cystectomy, before cystectomy. (EB, B, S)
324527
Clinicians should not prescribe carboplatin-based neoadjuvant chemotherapy for clinically resectable stage cT2-T4aN0 bladder cancer. Patients ineligible for cisplatin-based neoadjuvant chemotherapy should proceed to definitive locoregional therapy. (EO)
324527
Clinicians should perform radical cystectomy as soon as possible after a patient’s completion of and recovery from neoadjuvant chemotherapy. (EO)
324527
Eligible patients who have not received cisplatin-based neoadjuvant chemotherapy and have non–organ-confined (pT3/T4 and/or N+) disease at cystectomy should be offered adjuvant cisplatin-based chemotherapy. (EB, C, M)
324527
Radical cystectomy
Clinicians should offer radical cystectomy with bilateral pelvic lymphadenectomy for surgically eligible patients with resectable nonmetastatic (M0) muscle-invasive bladder cancer. (EB, B, S)
324527
When performing a standard radical cystectomy, clinicians should remove the bladder, prostate, and seminal vesicles in male patients and should remove the bladder, uterus, fallopian tubes, ovaries, and anterior vaginal wall in female patients. (CP)
324527
Clinicians should discuss and consider sexual function–preserving procedures for patients with organ-confined disease and absence of bladder neck, urethra, and prostate (male) involvement. (EB, C, M)
324527
Urinary diversion
In patients undergoing radical cystectomy, ileal conduit, continent cutaneous, and orthotopic neobladder urinary diversions should all be discussed. (CP)
324527
In patients receiving an orthotopic urinary diversion, clinicians must verify a negative urethral margin. (CP)
324527
Perioperative surgical management
Clinicians should attempt to optimize patient performance status in the perioperative setting. (EO)
324527
Perioperative pharmacologic thromboembolic prophylaxis should be given to patients undergoing radical cystectomy. (EB, B, S)
324527
In patients undergoing radical cystectomy, µ-opioid antagonist therapy should be used to accelerate GI recovery, unless contraindicated. (EB, B, S)
324527
Patients should receive detailed teaching regarding care of urinary diversion before discharge from the hospital . (CP)
324527
Pelvic lymphadenectomy
Clinicians must perform a bilateral pelvic lymphadenectomy at the time of any surgery with curative intent. (EB, B, S)
324527
When performing bilateral pelvic lymphadenectomy, clinicians should remove, at a minimum, the external and internal iliac and obturator lymph nodes (standard lymphadenectomy). (CP)
324527
Bladder-Preserving Approaches
Patient selection
For patients with newly diagnosed nonmetastatic muscle-invasive bladder cancer who desire to retain their bladder, and for those with significant comorbidities for whom radical cystectomy is not a treatment option, clinicians should offer bladder-preserving therapy when clinically appropriate. (CP)
324527
In patients under consideration for bladder-preserving therapy, maximal debulking TURBT and assessment of multifocal disease and carcinoma in situ should be performed. (EB, C, S)
324527
Maximal TURBT and partial cystectomy
Patients with muscle-invasive bladder cancer who are medically fit and consent to radical cystectomy should not undergo partial cystectomy or maximal TURBT as primary curative therapy. (EB, C, M)
324527
Primary radiation therapy
For patients with muscle-invasive bladder cancer, clinicians should not offer radiation therapy alone as a curative treatment. (EB, C, S)
324527
Multimodal bladder-preserving therapy
For patients with muscle-invasive bladder cancer who have elected multimodal bladder-preserving therapy, clinicians should offer maximal TURBT, chemotherapy combined with external beam radiation therapy, and planned cystoscopic re-evaluation. (EB, B, S)
324527
Radiation-sensitizing chemotherapy regimens should include cisplatin or fluorouracil and mitomycin C. (EB, B, S)
324527
After completion of bladder-preserving therapy, clinicians should perform regular surveillance with computed tomography scans, cystoscopy, and urine cytology. (EB, C, S)
324527
Bladder-preserving treatment failure
In patients who are medically fit and have residual or recurrent muscle-invasive disease after bladder-preserving therapy, clinicians should offer radical cystectomy with bilateral pelvic lymphadenectomy. (EB, C, S)
324527
In patients who have a non–muscle-invasive recurrence after bladder-preserving therapy, clinicians may offer either local measures, such as TURBT with intravesical therapy, or radical cystectomy with bilateral pelvic lymphadenectomy. (EB, C, M)
324527
Patient Surveillance and Follow-Up
Imaging
Clinicians should obtain chest imaging and cross-sectional imaging of the abdomen and pelvis with computed tomography or magnetic resonance imaging at 6- to 12-month intervals for 2 to 3 years and then may continue annually. (EO)
324527
Laboratory values and urine markers
After therapy for muscle-invasive bladder cancer, patients should undergo laboratory assessment at 3- to 6-month intervals for 2 to 3 years and then annually thereafter. (EO)
324527
After radical cystectomy in patients with a retained urethra, clinicians should monitor the urethral remnant for recurrence. (EO)
324527
Patient survivorship
linicians should discuss with patients how they are coping with their bladder cancer diagnosis and treatment and should recommend that patients consider participating in cancer support groups or consider receiving individual counseling. (EO)
324527
Clinicians should encourage patients with bladder cancer to adopt healthy lifestyle habits, including smoking cessation, exercise, and a healthy diet, to improve long-term health and quality of life. (EO)
324527
Variant Histology
In patients diagnosed with variant histology, clinicians should consider unique clinical characteristics that may require divergence from standard evaluation and management for urothelial carcinoma. (EO)
324527
Recommendation Grading
Overview
Title
Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer
Authoring Organizations
American Society for Radiation Oncology
American Society of Clinical Oncology
American Urological Association
Society of Urologic Oncology
Publication Month/Year
August 10, 2017
Last Updated Month/Year
January 17, 2024
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Target Patient Population
Patients with nonmetastatic muscle-invasive bladder cancer.
Inclusion Criteria
Female, Male, Adolescent, Adult, Child, Older adult
Health Care Settings
Ambulatory, Hospital, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Management, Treatment
Diseases/Conditions (MeSH)
D001749 - Urinary Bladder Neoplasms
Keywords
bladder cancer, Nonmetastatic Muscle-Invasive Bladder Cancer
Supplemental Methodology Resources
Methodology
Number of Source Documents
286
Literature Search Start Date
January 1, 1990
Literature Search End Date
May 18, 2020